Journal Watch: The DEPICT-1 52-Week Study

Originally published November 4, 2019 by Kathryn Thrailkill, MD, and Derick Adams, DO

This column highlights clinical trial data and landmark trials. Information for obtaining trial data and the references to the published articles are provided to facilitate discussion with your patients/colleagues. The trial is identified by the acronym and the National Clinical Trials Identifier. Primary outcome results are summarized.

Study Title: Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Study title acronym: DEPICT-1 identifier: NCT02268214

1. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552-2559.

2. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864-876.

Sponsor: AstraZeneca and Bristol-Myers Squibb

Study design: A multicenter, three-arm, parallel-group, phase 3 study that enrolled 833 adult participants with type 1 diabetes (T1D), ages 18-75 years with inadequate glycemic control (hemoglobinA1c [A1C] 7.5 to 10.5%) randomized 1:1:1 to treatment with once daily oral dapagliflozin 5 mg (n=277), 10 mg (n=296), or placebo (n=260), as add-on to adjustable insulin therapy. This 52-week blinded intervention study included a 24-week double-blinded short-term study (n=833)2 followed by a 28-week extension study (n=747 of original 833) to provide longer-term safety and efficacy data.

Primary outcomes: Change in A1C, percent change in total daily insulin dose and body weight, from baseline to week 52.

Other outcomes: Secondary outcomes assessed from baseline to week 52 included: 1) proportion of patients achieving an A1C reduction ≥0.5% with or without severe hypoglycemia; 2) proportion of patients with A1C < 7.0%; 3) change in fasting plasma glucose; 4) change in seated systolic blood pressure (SBP) among participants with baseline hypertension; and 5) cumulative safety outcomes data.

Results: Over 52 weeks of treatment, dapagliflozin (5 versus 10 versus placebo) as an adjunct to adjustable insulin therapy resulted in: 1) a clinically relevant reduction in A1C (8.2%, 8.2%, 8.5%; percent change: -0.27%, -0.31%, +0.06%, respectively); 2) a reduction in body weight (weight change: -2.31 kg, -3.65 kg, +0.25 kg; percent change: -2.80%, -4.39%, +0.15%); and 3) a significant reduction in total daily insulin. Additionally, patients treated with dapagliflozin experienced a greater reduction in fasting glucose and were more likely to achieve an A1C <7.0% or a ≥0.5% reduction in A1C without severe hypoglycemia (40.2%, 42.1%, 23.7%, respectively). These improvements came at the cost of slightly higher incidence of adverse events with dapagliflozin (13.4%, 13.5%, 11.5% of patients, respectively). Genital infections (more frequent in females than males) were increased with dapagliflozin (F/M: 21.5%/7.6%, 18.8%/8.6%, 6.3%/0%, respectively). Unlike the initial 24-week data from this trial2, diabetic ketoacidosis (DKA) events were unequivocally more common (4.0%, 3.4%, 1.9%, respectively).

Summary: An increasing number of studies are now reporting on the efficacy of sodium-glucose co-transporter 2 inhibitors as add-on to insulin in T1D over ~24 to 26 weeks of treatment. This study presents longer-term data with dapagliflozin to confirm yearlong improvements in glycemic control without hypoglycemia, accompanied by a sustained decrease in body weight. The increased risk for DKA, evident across a 52-week study (primarily related to missed or interrupted insulin administration), might result from delayed recognition of ketosis at lower glucose values. Therefore, the risk for DKA is a significant concern but perhaps preventable with increased education of both patients and health-care professionals regarding stricter attention to potential ketosis.

Access additional resources and practical information[1] designed to enhance the care and treatment of your diabetes patients.


Kathryn Thrailkill, MD[2]About our experts: Kathryn Thrailkill, MD, Professor of Pediatrics, Division of Pediatric Endocrinology, Barnstable Brown Endowed Chair in Pediatric Diabetes Research, Barnstable Brown Diabetes Center, University of Kentucky, Lexington, Kentucky



Derick Adams, DO[3]Derick Adams, DO, Assistant professor, internal medicine, Division of Endocrinology, Endocrinology Fellowship associate program director, Barnstable Brown Diabetes Center, University of Kentucky, Lexington, Kentucky

  1. resources and practical information:
  2. [Image]: //
  3. [Image]: //

Source URL:

Disclaimer Statements: Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.